Skip to main content

CureVac vaccine struggles in trial, particularly against variants

CureVac NV (Nasdaq: CVAC), headquartered in Germany with a U.S. office in Boston, announced on Wednesday that its Covid-19 vaccine candidate was just 47% effective against "any severity" of the disease in an interim analysis, failing to meet the criteria the company had initially laid out.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.